<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352414</url>
  </required_header>
  <id_info>
    <org_study_id>171044</org_study_id>
    <nct_id>NCT03352414</nct_id>
  </id_info>
  <brief_title>Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC</brief_title>
  <acronym>ILEUS</acronym>
  <official_title>The ILEUS Study: A Phase 2 Randomized Controlled Trial Investigating Alvimopan for Enhanced Gastrointestinal Recovery After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the ability of alvimopan to reduce the time to&#xD;
      return of bowel function in patients undergoing cytoreductive surgery and hyperthermic&#xD;
      intraperitoneal chemotherapy. Half of the participants will receive alvimopan or and half&#xD;
      will receive placebo immediately before and for up to seven days after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a&#xD;
      surgical procedure to treat cancer that has spread to the lining of the abdominal cavity&#xD;
      (peritoneal metastases). It is associated with a prolonged time for return of bowel function&#xD;
      after surgery.&#xD;
&#xD;
      Alvimopan is a drug used to speed up the time for return of bowel function after surgery. It&#xD;
      works by blocking the opioid receptors in the gastrointestinal tract, which normally slow&#xD;
      down bowel function in patients receiving postoperative opioid pain medication. It has not&#xD;
      previously been tested in patients undergoing CRS/HIPEC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    stopped by sponsor&#xD;
  </why_stopped>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Actual">April 28, 2020</completion_date>
  <primary_completion_date type="Actual">April 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Return of Upper and Lower GI Function</measure>
    <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
    <description>The later of the time from surgery that the participant first tolerates solid food and the time that the participant first passes a bowel movement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolonged Ileus</measure>
    <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
    <description>The proportion of patients who do not pass flatus or bowel movement greater than 7 days from the time of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return of Bowel Function Components</measure>
    <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
    <description>The time from surgery until:&#xD;
The time to first flatus&#xD;
The time to first bowel movement&#xD;
The time to tolerance of solid food</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
    <description>The time from surgery until discharge order written.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>up to 30 days from surgery</time_frame>
    <description>The number and proportion of serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup Analyses</measure>
    <time_frame>up to 30 days from surgery</time_frame>
    <description>All primary and secondary outcomes will be measured in the following subgroups:&#xD;
0 vs. 1 or greater bowel anastomoses&#xD;
0 vs. 1 or greater visceral resections&#xD;
high vs. low amount of postoperative opioid use&#xD;
epidural vs. no epidural</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Ileus</condition>
  <arm_group>
    <arm_group_label>Alvimopan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvimopan</intervention_name>
    <description>alvimopan pill</description>
    <arm_group_label>Alvimopan</arm_group_label>
    <other_name>Entereg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pill</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
          -  Scheduled to undergo open (non-minimally invasive) CRS/HIPEC.&#xD;
&#xD;
          -  Scheduled to receive postoperative pain management with intravenous opioids.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status â‰¤ 2.&#xD;
&#xD;
          -  Women of child-bearing potential with negative pregnancy test prior to initiating&#xD;
             study drug dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Greater than 7 days of consecutive opioid use immediately prior to scheduled surgery.&#xD;
&#xD;
          -  Child-Pugh Class C hepatic impairment.&#xD;
&#xD;
          -  End-stage renal disease (GFR &lt; 15 mL/min/1.73 m2 and/or on peritoneal dialysis or&#xD;
             hemodialysis).&#xD;
&#xD;
          -  Complete mechanical bowel obstruction.&#xD;
&#xD;
          -  Contraindication or inability to tolerate oral medication postoperatively.&#xD;
&#xD;
          -  Presence of gastrointestinal ostomy after CRS/HIPEC.&#xD;
&#xD;
          -  Pancreatic or gastric anastomosis performed during CRS/HIPEC.&#xD;
&#xD;
          -  History of allergic reactions or hypersensitivity attributed to compounds of similar&#xD;
             chemical or biologic composition as alvimopan at the treating investigators&#xD;
             discretion.&#xD;
&#xD;
          -  Severe or uncontrolled medical disorder that would, in the investigator's opinion,&#xD;
             impair ability to receive study treatment (i.e. uncontrolled diabetes, chronic renal&#xD;
             disease, chronic pulmonary disease or active, uncontrolled infection, psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements).&#xD;
&#xD;
          -  History of myocardial infarction in the 12 months prior to scheduled surgery.&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Baumgartner, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0987</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 18, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <results_first_submitted>April 13, 2021</results_first_submitted>
  <results_first_submitted_qc>June 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Joel Baumgartner</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <keyword>peritoneal carcinomatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ileus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alvimopan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study was terminated early</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03352414/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>84 participants were enrolled and randomized (constitute the safety population). All participants must later meet surgical eligibility for final allocation and analysis (n=62).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alvimopan</title>
          <description>Alvimopan: alvimopan pill</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: placebo pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Allocated</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible by operative criteria</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alvimopan</title>
          <description>Alvimpan Arm</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="27" upper_limit="73"/>
                    <measurement group_id="B2" value="61" lower_limit="28" upper_limit="79"/>
                    <measurement group_id="B3" value="57" lower_limit="27" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Return of Upper and Lower GI Function</title>
        <description>The later of the time from surgery that the participant first tolerates solid food and the time that the participant first passes a bowel movement.</description>
        <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
        <population>Study was terminated early, preliminary data</population>
        <group_list>
          <group group_id="O1">
            <title>Alvimopan</title>
            <description>Alvimopan: alvimopan pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return of Upper and Lower GI Function</title>
          <description>The later of the time from surgery that the participant first tolerates solid food and the time that the participant first passes a bowel movement.</description>
          <population>Study was terminated early, preliminary data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="102" upper_limit="158"/>
                    <measurement group_id="O2" value="152" lower_limit="134" upper_limit="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Ileus</title>
        <description>The proportion of patients who do not pass flatus or bowel movement greater than 7 days from the time of surgery.</description>
        <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
        <population>Study was terminated early, preliminary data</population>
        <group_list>
          <group group_id="O1">
            <title>Alvimopan</title>
            <description>Alvimopan: alvimopan pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Ileus</title>
          <description>The proportion of patients who do not pass flatus or bowel movement greater than 7 days from the time of surgery.</description>
          <population>Study was terminated early, preliminary data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return of Bowel Function Components</title>
        <description>The time from surgery until:&#xD;
The time to first flatus&#xD;
The time to first bowel movement&#xD;
The time to tolerance of solid food</description>
        <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
        <population>Study was terminated early, preliminary data</population>
        <group_list>
          <group group_id="O1">
            <title>Alvimopan</title>
            <description>Alvimopan: alvimopan pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return of Bowel Function Components</title>
          <description>The time from surgery until:&#xD;
The time to first flatus&#xD;
The time to first bowel movement&#xD;
The time to tolerance of solid food</description>
          <population>Study was terminated early, preliminary data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to first flatus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="51" upper_limit="93"/>
                    <measurement group_id="O2" value="79" lower_limit="63" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to first BM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="62" upper_limit="89"/>
                    <measurement group_id="O2" value="89" lower_limit="71" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time to tolerance of solid food</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="102" upper_limit="158"/>
                    <measurement group_id="O2" value="149" lower_limit="134" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge</title>
        <description>The time from surgery until discharge order written.</description>
        <time_frame>from surgery to discharge (generally no longer than two weeks)</time_frame>
        <population>Study was terminated early, preliminary data</population>
        <group_list>
          <group group_id="O1">
            <title>Alvimopan</title>
            <description>Alvimpan Arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Arm</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge</title>
          <description>The time from surgery until discharge order written.</description>
          <population>Study was terminated early, preliminary data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="147" upper_limit="212"/>
                    <measurement group_id="O2" value="190" lower_limit="187" upper_limit="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>The number and proportion of serious adverse events.</description>
        <time_frame>up to 30 days from surgery</time_frame>
        <population>From Safety population (n=84) Study was terminated early, preliminary data</population>
        <group_list>
          <group group_id="O1">
            <title>Alvimopan</title>
            <description>Alvimopan: alvimopan pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>The number and proportion of serious adverse events.</description>
          <population>From Safety population (n=84) Study was terminated early, preliminary data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subgroup Analyses</title>
        <description>All primary and secondary outcomes will be measured in the following subgroups:&#xD;
0 vs. 1 or greater bowel anastomoses&#xD;
0 vs. 1 or greater visceral resections&#xD;
high vs. low amount of postoperative opioid use&#xD;
epidural vs. no epidural</description>
        <time_frame>up to 30 days from surgery</time_frame>
        <population>Study was terminated early, data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Alvimopan</title>
            <description>Alvimopan: alvimopan pill</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: placebo pill</description>
          </group>
        </group_list>
        <measure>
          <title>Subgroup Analyses</title>
          <description>All primary and secondary outcomes will be measured in the following subgroups:&#xD;
0 vs. 1 or greater bowel anastomoses&#xD;
0 vs. 1 or greater visceral resections&#xD;
high vs. low amount of postoperative opioid use&#xD;
epidural vs. no epidural</description>
          <population>Study was terminated early, data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days from the the time of surgery</time_frame>
      <desc>CTCAE v 4.03 (grade 3 or higher considered serious adverse event) All participants in the safety population (n=84) were included in the adverse event analysis. Per the protocol, this includes all randomized patients who took at least one dose of the study medication, including screen failures (at the time of surgery) after randomization and subjects withdrawn from the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alvimopan</title>
          <description>Alvimopan: alvimopan pill</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: placebo pill</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rectal Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastric Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Non-Serious Adverse Events</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="42"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond Diep, Clinical Research Coordinator</name_or_title>
      <organization>University of California, San Diego</organization>
      <phone>(858) 822-5352</phone>
      <email>rhdiep@health.ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

